       Document 0813
 DOCN  M9590813
 TI    Beneficial effect of recombinant human granulocyte colony-stimulating
       factor on fungicidal activity of polymorphonuclear leukocytes from
       patients with AIDS.
 DT    9509
 AU    Vecchiarelli A; Monari C; Baldelli F; Pietrella D; Retini C; Tascini C;
       Francisci D; Bistoni F; Department of Experimental Medicine and
       Biochemical Sciences,; University of Perugia, Italy.
 SO    J Infect Dis. 1995 Jun;171(6):1448-54. Unique Identifier : AIDSLINE
       MED/95287034
 AB    The effect of recombinant human granulocyte colony-stimulating factor
       (rhG-CSF) administration on the functional status of polymorphonuclear
       leukocytes (PMNL) in neutropenic AIDS patients was investigated. PMNL
       destructive activity against Candida albicans or encapsulated or
       acapsular Cryptococcus neoformans was significantly impaired with
       respect to control subjects before rhG-CSF treatment. After subcutaneous
       administration of rhG-CSF (5 micrograms/kg), neutrophil counts increased
       3- to 11-fold in 24 h and returned to baseline within 96 h. PMNL
       fungicidal activity showed significant enhancement 48-72 h after rhG-CSF
       administration that decreased to baseline within 96 h. Enhanced
       rhG-CSF-mediated destructive activity strictly correlated with augmented
       superoxide anion production by PMNL. These findings suggest that
       therapeutic use of rhG-CSF at appropriate schedules in neutropenic AIDS
       patients could decrease the risk of infection or, in association with
       antibiotic therapy, more rapidly resolve the occurring infections.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS/DRUG THERAPY/
       *IMMUNOLOGY  Adult  Candida albicans/IMMUNOLOGY  Cryptococcus
       neoformans/IMMUNOLOGY  Cytotoxicity, Immunologic  Granulocyte
       Colony-Stimulating Factor/*THERAPEUTIC USE  Human  Immunity, Cellular
       Mycoses/COMPLICATIONS/*IMMUNOLOGY  Neutropenia/COMPLICATIONS
       Neutrophils/*IMMUNOLOGY  Phagocytosis/DRUG EFFECTS  Recombinant Proteins
       Respiratory Burst/DRUG EFFECTS  Superoxides/METABOLISM  Support,
       Non-U.S. Gov't  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

